Singapore, August 31 2020 - Vela Diagnostics announced today the launch of the OncoKey™ SL 60 Plus Assay. The assay is a next-generation sequencing (NGS)-based, pan-cancer test that detects single nucleotide variations (SNVs), insertions/deletions (INDELs), copy number variations (CNVs), microsatellite instability (MSI), fusions and oncogenic pathogens in more than 60 targeted genes, in formalin-fixed paraffin-embedded (FFPE) tissue specimens.
The OncoKey™ SL 60 Plus Assay, available for research use, is intended for use on the automated Sentosa™ NGS workflow using Sentosa™ SX101,in conjunction with Illumina® Miseq™ or NextSeq™ sequencing systems. The workflow requires as little as 40 ng DNA or RNA per library and detects mutations as low as 5% variant allele frequency.
The automated workflow reduces hands-on time to a minimum and provides completely automated reporting of QC and test results for cancer samples. Data can be further analyzed with the VELA™ Analytics software, which provides a comprehensive interpretation of clinically actionable variants and variant categorization according to professional guidelines.
“Genetic mutation testing aids physicians in selecting the appropriate cancer treatment for patients, and provides insights into cancer prognosis. Our OncoKey™ SL Plus panels offer a cost-effective and flexible solution that targets clinically relevant genes for the most common cancer types, providing clinical insights in precision medicine research,” said Dr. Charlie Lee, Head of Research and Development.
The OncoKey™ SL 60 Plus Assay is the first product in Vela Diagnostics’ OncoKey™ SL portfolio that provides flexible automated NGS solutions for oncology to laboratories. Upcoming solutions include the OncoKey™ SL 190 Plus and OncoKey™ SL 525 Plus assays, which will be able to provide even greater genomic coverage across multiple cancer types.
About Vela Diagnostics
Vela Diagnostics is a leading provider for integrated IVD system solutions, from sample to result. VELA’s test solutions utilize the automated Sentosa™ platform, providing the unique ability to leverage one system for NGS and PCR testing in infectious disease and oncology.
All Sentosa™ products listed above are by Vela Diagnostics. For more information, visit www.veladx.com.